Division of Cardiology, Ross 858, Department of Medicine, Johns Hopkins University Medical Institutions, 720 Rutland Avenue, Baltimore, MD 21205, USA.
J Mol Cell Cardiol. 2010 Apr;48(4):713-24. doi: 10.1016/j.yjmcc.2009.11.015. Epub 2009 Dec 1.
Increased cyclic GMP from enhanced synthesis or suppressed catabolism (e.g. PDE5 inhibition by sildenafil, SIL) activates protein kinase G (PKG) and blunts cardiac pathological hypertrophy. Suppressed calcineurin (Cn)-NFAT (nuclear factor of activated T-cells) signaling appears to be involved, though it remains unclear how this is achieved. One potential mechanism involves activation of Cn/NFAT by calcium entering via transient receptor potential canonical (TRPC) channels (notably TRPC6). Here, we tested the hypothesis that PKG blocks Cn/NFAT activation by modifying and thus inhibiting TRPC6 current to break the positive feedback loop involving NFAT and NFAT-dependent TRPC6 upregulation. TRPC6 expression rose with pressure-overload in vivo, and angiotensin (ATII) or endothelin (ET1) stimulation in neonatal and adult cardiomyocytes in vitro. 8Br-cGMP and SIL reduced ET1-stimulated TRPC6 expression and NFAT dephosphorylation (activity). TRPC6 upregulation was absent if its promoter was mutated with non-functional NFAT binding sites, whereas constitutively active NFAT triggered TRPC6 expression that was not inhibited by SIL. PKG phosphorylated TRPC6, and both T70 and S322 were targeted. Both sites were functionally relevant, as 8Br-cGMP strongly suppressed current in wild-type TRPC6 channels, but not in those with phospho-silencing mutations (T70A, S322A or S322Q). NFAT activation and increased protein synthesis stimulated by ATII or ET1 was blocked by 8Br-cGMP or SIL. However, transfection with T70A or S322Q TRPC6 mutants blocked this inhibitory effect, whereas phospho-mimetic mutants (T70E, S322E, and both combined) suppressed NFAT activation. Thus PDE5-inhibition blocks TRPC6 channel activation and associated Cn/NFAT activation signaling by PKG-dependent channel phosphorylation.
循环 GMP 的增加来自于合成的增强或分解代谢的抑制(例如,西地那非、SIL 对 PDE5 的抑制),激活蛋白激酶 G(PKG),并抑制心脏病理性肥大。抑制钙调神经磷酸酶(Cn)-NFAT(活化 T 细胞核因子)信号似乎涉及其中,但尚不清楚这是如何实现的。一种潜在的机制涉及钙通过瞬时受体电位经典型(TRPC)通道(特别是 TRPC6)进入后激活 Cn/NFAT。在这里,我们通过改变和抑制 TRPC6 电流来测试 PKG 通过阻断涉及 NFAT 和 NFAT 依赖性 TRPC6 上调的正反馈环来阻断 Cn/NFAT 激活的假设,TRPC6 电流的改变和抑制 TRPC6 电流来阻断涉及 NFAT 和 NFAT 依赖性 TRPC6 上调的正反馈环。体内压力超负荷时 TRPC6 表达增加,体外培养的新生和成年心肌细胞中血管紧张素(ATII)或内皮素(ET1)刺激时也会增加。8Br-cGMP 和 SIL 减少 ET1 刺激的 TRPC6 表达和 NFAT 去磷酸化(活性)。如果其启动子发生突变,使其失去非功能 NFAT 结合位点,则不存在 TRPC6 上调,而组成型激活的 NFAT 触发的 TRPC6 表达不受 SIL 抑制。PKG 磷酸化 TRPC6,T70 和 S322 均为其靶点。这两个位点都是功能相关的,因为 8Br-cGMP 强烈抑制野生型 TRPC6 通道的电流,但不抑制磷酸化沉默突变体(T70A、S322A 或 S322Q)的电流。ATII 或 ET1 刺激的 NFAT 激活和增加的蛋白质合成被 8Br-cGMP 或 SIL 阻断。然而,用 T70A 或 S322Q TRPC6 突变体转染阻断了这种抑制作用,而磷酸化模拟突变体(T70E、S322E 和两者的组合)则抑制了 NFAT 的激活。因此,PDE5 抑制通过 PKG 依赖性通道磷酸化阻断 TRPC6 通道激活和相关的 Cn/NFAT 激活信号。